Suppr超能文献

评估记忆衰退速度与阿尔茨海默病风险的遗传结构。

Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline.

机构信息

Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.

Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

J Alzheimers Dis. 2018;62(2):745-756. doi: 10.3233/JAD-170834.

Abstract

Many genetic studies for Alzheimer's disease (AD) have been focused on the identification of common genetic variants associated with AD risk and not on other aspects of the disease, such as age at onset or rate of dementia progression. There are multiple approaches to untangling the genetic architecture of these phenotypes. We hypothesized that the genetic architecture of rate of progression is different than the risk for developing AD dementia. To test this hypothesis, we used longitudinal clinical data from ADNI and the Knight-ADRC at Washington University, and we calculated PRS (polygenic risk score) based on the IGAP study to compare the genetic architecture of AD risk and dementia progression. Dementia progression was measured by the change of Clinical Dementia Rating Sum of Boxes (CDR)-SB per year. Out of the 21 loci for AD risk, no association with the rate of dementia progression was found. The PRS rate was significantly associated with the rate of dementia progression (β= 0.146, p = 0.03). In the case of rare variants, TREM2 (β= 0.309, p = 0.02) was also associated with the rate of dementia progression. TREM2 variant carriers showed a 23% faster rate of dementia compared with non-variant carriers. In conclusion, our results indicate that the recently identified common and rare variants for AD susceptibility have a limited impact on the rate of dementia progression in AD patients.

摘要

许多针对阿尔茨海默病(AD)的遗传研究都集中在识别与 AD 风险相关的常见遗传变异体上,而不是关注疾病的其他方面,例如发病年龄或痴呆进展速度。有多种方法可以理清这些表型的遗传结构。我们假设进展速度的遗传结构与发生 AD 痴呆的风险不同。为了检验这一假设,我们使用了 ADNI 和华盛顿大学 Knight-ADRC 的纵向临床数据,并根据 IGAP 研究计算了 PRS(多基因风险评分),以比较 AD 风险和痴呆进展的遗传结构。痴呆进展通过每年临床痴呆评定量表总和评分(CDR-SB)的变化来衡量。在 21 个 AD 风险相关的基因座中,没有发现与痴呆进展速度相关的关联。PRS 率与痴呆进展速度显著相关(β=0.146,p=0.03)。在罕见变异的情况下,TREM2(β=0.309,p=0.02)也与痴呆进展速度相关。与非变异携带者相比,TREM2 变异携带者的痴呆进展速度快 23%。总之,我们的结果表明,最近确定的 AD 易感性的常见和罕见变异体对 AD 患者的痴呆进展速度的影响有限。

相似文献

1
Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline.
J Alzheimers Dis. 2018;62(2):745-756. doi: 10.3233/JAD-170834.
3
TREM2 risk variants and associated endophenotypes in alzheimer's disease.
Alzheimers Res Ther. 2025 Mar 6;17(1):57. doi: 10.1186/s13195-025-01700-2.
4
R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia.
Alzheimers Dement. 2014 Nov;10(6):602-608.e4. doi: 10.1016/j.jalz.2014.05.1751. Epub 2014 Aug 23.
6
Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia.
Neurobiol Aging. 2014 Feb;35(2):444.e1-4. doi: 10.1016/j.neurobiolaging.2013.08.011. Epub 2013 Sep 13.
7
Coding variants in TREM2 increase risk for Alzheimer's disease.
Hum Mol Genet. 2014 Nov 1;23(21):5838-46. doi: 10.1093/hmg/ddu277. Epub 2014 Jun 4.
10
Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia.
Neurobiol Aging. 2014 Mar;35(3):726.e11-9. doi: 10.1016/j.neurobiolaging.2013.09.009. Epub 2013 Oct 9.

引用本文的文献

1
Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum.
Neuron. 2025 May 7;113(9):1363-1379.e9. doi: 10.1016/j.neuron.2025.02.014. Epub 2025 Mar 14.
2
Patient stratification by genetic risk in Alzheimer's disease is only effective in the presence of phenotypic heterogeneity.
PLoS One. 2025 Jan 9;20(1):e0310977. doi: 10.1371/journal.pone.0310977. eCollection 2025.
3
Comparison of Ensemble Techniques for Early Prediction of Alzhiemer Disease.
Res Sq. 2024 Dec 23:rs.3.rs-5644910. doi: 10.21203/rs.3.rs-5644910/v1.
4
Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model.
Neuron. 2024 Dec 4;112(23):3877-3896.e8. doi: 10.1016/j.neuron.2024.09.006. Epub 2024 Sep 30.
5
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism.
Alzheimers Dement. 2024 Sep;20(9):5861-5888. doi: 10.1002/alz.13921. Epub 2024 Aug 1.
7
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease.
Alzheimers Dement. 2024 Sep;20(9):6205-6220. doi: 10.1002/alz.14103. Epub 2024 Jul 6.
8
Cluster Analysis of Cortical Amyloid Burden for Identifying Imaging-driven Subtypes in Mild Cognitive Impairment.
AMIA Jt Summits Transl Sci Proc. 2024 May 31;2024:439-448. eCollection 2024.

本文引用的文献

2
Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms.
Alzheimers Dement. 2018 Feb;14(2):205-214. doi: 10.1016/j.jalz.2017.08.013. Epub 2017 Sep 21.
3
An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis.
Biol Psychiatry. 2017 Mar 15;81(6):470-477. doi: 10.1016/j.biopsych.2016.06.028. Epub 2016 Aug 6.
4
Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease.
Neurobiol Aging. 2017 Jan;49:214.e7-214.e11. doi: 10.1016/j.neurobiolaging.2016.07.018. Epub 2016 Aug 5.
5
Reflections on the Field of Human Genetics: A Call for Increased Disease Genetics Theory.
Front Genet. 2016 Jun 8;7:106. doi: 10.3389/fgene.2016.00106. eCollection 2016.
6
ABCA7 p.G215S as potential protective factor for Alzheimer's disease.
Neurobiol Aging. 2016 Oct;46:235.e1-9. doi: 10.1016/j.neurobiolaging.2016.04.004. Epub 2016 Apr 20.
7
TREM2 Function in Alzheimer's Disease and Neurodegeneration.
ACS Chem Neurosci. 2016 Apr 20;7(4):420-7. doi: 10.1021/acschemneuro.5b00313. Epub 2016 Feb 19.
8
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
Acta Neuropathol. 2016 Jun;131(6):925-33. doi: 10.1007/s00401-016-1533-5. Epub 2016 Jan 11.
9
Role of ABCA7 loss-of-function variant in Alzheimer's disease: a replication study in European-Americans.
Alzheimers Res Ther. 2015 Dec 10;7(1):73. doi: 10.1186/s13195-015-0154-x.
10
Marked gender differences in progression of mild cognitive impairment over 8 years.
Alzheimers Dement (N Y). 2015 Sep 1;1(2):103-110. doi: 10.1016/j.trci.2015.07.001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验